Novel ketolide antibiotics with a fused five-membered lactone ring - Synthesis, physicochemical and antimicrobial properties

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 13, 2004, Pages 3503-3519

  Hunziker, Daniel ^a   Wyss, Pierre C ^a   Angehrn, Peter ^a   Mueller, Aranka ^a   Marty, Hans Peter ^a   Halm, Remy ^a   Kellenberger, Laurenz ^b   Bitsch, Veronique ^b   Biringer, Gerard ^b   Arnold, Wolf ^a   Stämpfli, Andreas ^a   Schmitt Hoffmann, Anne ^b   Cousot, Denis ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

Antibiotic; Antiinfective; Ketolide; Ketolide antibiotic; Macrolide; Macrolide antibiotic

Indexed keywords

15 ETHYLOCTAHYDRO 8 METHOXY 4,6,8,10,12,15A HEXAMETHYL 3 [[3 (PYRIDIN 4 YL)PROPYL]THIO] 9 [[3,4,6 TRIDEOXY 3 (DIMETHYLAMINO) BETA DEXTRO XYLOHEXOPYRANOSYL]OXY] 2H FURO[2,3 C]OXACYCLOTETRADECIN 2,5,11,13(3H,6H,12H) TETRONE; 3 [[2 (6 AMINO 9H PURIN 9 YL)ETHYL]THIO] 15 ETHYLOCTAHYDRO 8 METHOXY 4,6,8,10,12,15A HEXAMETHYL 9 [[3,4,6 TRIDEOXY 3 (DIMETHYLAMINO) BETA DEXTRO XYLOHEXOPYRANOSYL]OXY] 2H FURO[2,3 C]OXACYCLOTETRADECIN 2,5,11,13(3H,6H,12H) TETRONE; KETOLIDE; LACTONE; PYRAN DERIVATIVE; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CHEMICAL BOND; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; MICHAEL ADDITION; NONHUMAN; PHYSICAL CHEMISTRY;

ANIMALS; ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; HAEMOPHILUS INFLUENZAE; INHIBITORY CONCENTRATION 50; KETOLIDES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MOLECULAR STRUCTURE; SOLUBILITY; STEREOISOMERISM; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 2942512154     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.04.039     Document Type: Article

References (34)

1. Bryskier A.J., Butzler J.-P., Neu H.C., Tulkens P.M. Macrolides: Chemistry. Pharmacology and Clinical Uses. 1993;Arnette Blackwell, Paris
2. Morimoto S., Takahashi Y., Watanabe Y., Omura S. J. Antibiot. 37:1984;187-189
3. Chantot J.-F., Bryskier A.J., Gasc J.-C. J. Antibiot. 39:1986;660-668
4. Retsema J.A., Girard A.E., Schekly W., Manousos M., Anderson M.R., Bright G.M., Borovoy R.J., Brennan L.A., Mason R. Antimicrob. Agents Chemother. 31:1987;1939-1947
5. Agouridas C., Denis A., Auger J.-M., Benedetti Y., Bonnefoy A., Bretin F., Chantot J.-F., Dussarat A., Fromentin C., Gouin d'Ambrieres S., Lachaud S., Laurin P., Le Martret O.L., Loyau V., Tessot N. J. Med. Chem. 41:1998;4080-4100
6. Denis A., Agouridas C., Auger J.-M., Benedetti Y., Bonnefoi A., Bretin F., Chantot J.-F., Dussarat A., Fromentin C., Gouin d'Ambrieres S., Lachaud S., Laurin P., Le Martet O., Loyau V., Tessot N., Pejac J.-M., Perron S. Bioorg. Med. Chem. Lett. 9:1999;3075-3080
7. (b) Agouridas, C.; Chantot, J.-F.; Denis, A.; Gouin d'Ambrieres, S.; Le Martet, O. Fr. Demande FR 2732684 A1, 1996
8. (b) Agouridas, C.; Chantot, J.-F.; Denis, A.; Gouin d'Ambrieres, S.; Le Martet, O. Eur. Pat. Appl. EP 95-400987, 1995
9. Or Y.S., Clark R.F., Wang S., Chu D.T.W., Nilius A.M., Flamm R.K., Mitten M., Ewing P., Alder J., Ma Z. J. Med. Chem. 43:2000;1045-1049
10. (b) Or, Y. S.; Ma, Z.; Clark, R. F.; Chu, D. T.; Plattner, J. J. PCT Int. Appl. WO 9809978 A1, 1998
11. For synthetic aspects concerning ABT733 see: Stoner E.J., Peterson M.J., Allen M.S., DeMattei J.A., Haight A.R., Leanna M.R., Patel S.R., Plata D.J., Premchandran R.H., Rasmussen M. J. Org. Chem. 68:2003;8847-8852. and references cited therein
12. (a) Phan, L. T.; Or, Y. S.; Chu, D. T.; Plattner, J. J.; Chen, Y.; Clark, R. F. PCT Int. Appl. WO 9921871 A1, 1999
13. (b) Bonnet, A.; Gambier, F. Eur. Pat. Appl. EP 949268 A1, 1999
14. Denis A., Bretin F., Fromentin C., Bonnet A., Piltan G., Bonnefoy A., Agouridas C. Bioorg. Med. Chem. Lett. 10:2000;2019-2022
15. Blondeau J.M., DeCarolis E., Metzler K., Hansen G.T. Exp. Opin. Invest. Drugs. 11:2002;189-215
16. Wu Y.-J., Su W.-G. Curr. Med. Chem. 8:2001;1727-1758
17. Kaneko T., McArthur H., Sutcliffe J. Exp. Opin. Therap. Pat. 10:2000;403-425
18. Bryskier A. Exp. Opin. Invest. Drugs. 8:1999;1171-1194
19. Slawinski W., Bojarska-Dahlig H., Glabski T., Dziegielwska I., Biedrzycki M., Naperty S. Recl. Chim. Pays-Bas. 94:1975;236-238
20. Baker W.R., Clark J.D., Stephens R.L., Kim K.H. J. Org. Chem. 53:1988;2340-2345
21. For the corresponding derivative of 1, see: Hauske J.R., Kostek G. J. Org. Chem. 47:1982;1595-1596
22. (a) Andreotti, D.; Biondi, S.; Lociuro, S. PCT Int. Appl. WO 0250092 A1, 2002
23. (b) Andreotti, D.; Arista, L.; Biondi, S.; Cardullo, F.; Damiani, F.; Lociuro, S.; Marchioro, C.; Merlo, G.; Mingardi, A.; Niccolai, D.; Paio, A.; Piga, E.; Pozzan, A.; Seri, C.; Tarsi, L.; Terreni, S.; Tibasco, J. PCT. Int. Appl. WO 0250091 A1, 2002
24. Von Braun J., Weissbach K. Chem. Ber. 62:1929;2416-2425
25. Il'ichev Y.E., Grinchenko T.V., Salimov M.A., Il'ichev I.E., Rukhadze E.G., Terent'ev A.P. J. Org. Chem. USSR. 7:1971;2511-2515
26. It has been brought to our attention that this apparent ester formation might actually be the result of a ketene addition to the tertiary hydroxy group at position C(12)
27. 3
28. LeMahieu R.A., Carson M., Kierstead R.W., Fern L.M., Grunberg E. J. Med. Chem. 17:1974;953-956
29. Angehrn, P.; Hunziker, D.; Wyss, P.-C. PCT Int. Appl. WO 0216380 A1, 2002
30. Steinmetz W.E., Bersch R., Towson J., Pesiri D. J. Med. Chem. 35:1992;4842-4845
31. Clemo G.R., Holmes T., Leitch G.C. J. Chem. Soc. 1934;753-755
32. Schunack W. Arch. Pharmaz. 306:1973;934-942
33. Lin Y.-I., Lang S.A. Jr., Lovell M.F., Perkinson N.A. J. Org. Chem. 44:1979;4160-4164
34. Schall O.F., Gokel G.W. J. Am. Chem. Soc. 116:1994;6089-6100